Fasinex 240 mg/ml oral suspension for cattle

Χώρα: Ιρλανδία

Γλώσσα: Αγγλικά

Πηγή: HPRA (Health Products Regulatory Authority)

Δραστική ουσία:

Triclabendazole

Διαθέσιμο από:

Elanco Europe Ltd

Φαρμακολογική κατηγορία (ATC):

QP52AC01

INN (Διεθνής Όνομα):

Triclabendazole

Δοσολογία:

240 milligram(s)/millilitre

Φαρμακοτεχνική μορφή:

Oral suspension

Τρόπος διάθεσης:

LM: Licensed Merchant as defined in relevant national legislation

Θεραπευτική ομάδα:

Cattle

Θεραπευτική περιοχή:

triclabendazole

Θεραπευτικές ενδείξεις:

Endoparasiticide

Καθεστώς αδειοδότησης:

Authorised

Ημερομηνία της άδειας:

2008-09-05

Αρχείο Π.Χ.Π.

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Fasinex 240 mg/ml oral suspension for cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Oral Suspension.
White to cream-coloured aqueous suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of acute, subacute and chronic infection due to
early immature, immature, and mature stages of
_Fasciola hepatica_. If infected animals are treated before disease
has developed, fasciolosis can be prevented.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substance or to
any of the ingredients.
ACTIVE SUBSTANCE:
Triclabendazole
240 mg
EXCIPIENTS:
Methyl parahydroxybenzoate (E218)
1.1 mg
Propyl parahydroxybenzoate (E216)
0.4 mg
Benzyl alcohol (E1519)
5.0 mg
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_1_
_/_
_1_
_0_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_2_
_9_
_9_
_5_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk of development of resistance and
could ultimately result in ineffective therapy.
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
Underdosing, which may be due to underestimation of bodyweight,
misadministrati